Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
Helen Gogas(National and Kapodistrian University of Athens), Caroline Robert(Institut Gustave Roussy), Ivana Krajsová(Charles University), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Gabriella Liszkay(National Institute of Oncology), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Keith T. Flaherty(Cancer Research Center), Jan Willem B. de Groot(Isala), Claus Garbe(University of Tübingen), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Dirk Schadendorf(National Center for Tumor Diseases), Ashwin Gollerkeri(Peter MacCallum Cancer Centre), Michael D. Pickard(Peter MacCallum Cancer Centre), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Carmen Loquai(Johannes Gutenberg University Mainz), Reinhard Dummer(University Hospital of Zurich), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Naoya Yamazaki(Tokyo National Hospital)
Cited by 81
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k